信立泰(002294) - 2014 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥679,287,177.42, representing a year-on-year growth of 20.70%[4] - Net profit attributable to shareholders of the listed company was ¥256,140,870.24, up 28.19% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥254,152,264.42, an increase of 27.21% year-on-year[4] - Basic earnings per share for the reporting period were ¥0.39, reflecting a growth of 25.81%[4] - The estimated net profit attributable to shareholders for 2014 is expected to range from 99,649.99 million to 107,954.16 million RMB, representing a growth of 20.00% to 30.00% compared to the previous year[21] - The net profit for 2013 attributable to shareholders was 83,041.66 million RMB, indicating a stable growth in sales of the company's formulation products[21] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,904,559,939.47, an increase of 7.17% compared to the end of the previous year[4] - Net assets attributable to shareholders of the listed company amounted to ¥3,488,432,591.11, reflecting an increase of 11.48% year-on-year[4] - Other current assets increased by CNY 300.20 million, a growth of 149.69%, mainly due to the purchase of financial products during the reporting period[14] - Deferred tax assets increased by CNY 12.51 million, a growth of 31.72%, primarily due to the increase in unrealized internal transactions during the reporting period[14] - Accounts payable decreased by CNY 64.29 million, a reduction of 38.48%, mainly due to the decrease in payable engineering and equipment costs during the reporting period[14] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥678,387,934.43, an increase of 44.23%[4] - Cash received from sales of goods and services increased by CNY 520.25 million, a growth of 34.62%, mainly due to increased sales and cash receipts[14] - Cash paid for other operating activities increased by CNY 160.30 million, a growth of 46.55%, primarily due to increased expenses during the reporting period[14] - Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets decreased by CNY 218.22 million, a reduction of 56.88%, mainly due to prepayments made in the previous period for the acquisition of production technology[15] - Cash paid for investments increased by CNY 502.00 million, a growth of 502.00%, primarily due to the purchase of financial products during the reporting period[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 30,409[9] - The largest shareholder, Xintai Pharmaceutical Co., Ltd., holds 71.56% of the shares, totaling 467,812,800 shares[9] Compliance and Investments - The company has not engaged in any securities investments during the reporting period[22] - The company does not hold shares in any other listed companies during the reporting period[23] - The commitments made by the company's controlling shareholders have been fulfilled without any violations[20] Non-Recurring Items - Non-recurring gains and losses for the year-to-date totaled ¥7,030,349.09[6]